{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:16:46Z","timestamp":1771222606363,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neuromuscular disease with marked phenotypic and clinical heterogeneity. Three active pharmaceutical agents are currently approved by the United States Food and Drug Administration (FDA) for ALS: riluzole, edaravone (including intravenous [IV] and oral suspension formulations), and tofersen. Study MCI186\u201019 (Study 19) was a pivotal, phase 3 randomized controlled trial that demonstrated a significant reduction in physical functional decline vs. placebo in Japanese patients with ALS and contributed to FDA approval of IV edaravone in 2017. Edaravone oral suspension was FDA\u2010approved in May 2022 following the results of Study MT\u20101186\u2010A01, which showed it was well tolerated with a safety profile consistent with IV edaravone. Following Study 19, the clinical benefit of edaravone has remained an active area of investigation. This supplement presents data from clinical trials, post hoc analyses, and clinical studies that expand understanding of the use of edaravone in broader ALS populations. Topics include safety in clinical practice, generalizability of efficacy, clinical treatment outcomes, and health economics and outcomes research studies. Together, these findings aim to inform clinicians, researchers, and stakeholders regarding the evolving evidence base for edaravone in the management of ALS.<\/jats:p>","DOI":"10.1002\/mus.70036","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:29:44Z","timestamp":1770460184000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Introduction to the Supplement"],"prefix":"10.1002","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8826","authenticated-orcid":false,"given":"Kelly G.","family":"Gwathmey","sequence":"first","affiliation":[{"name":"Department of Neurology Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-3953","authenticated-orcid":false,"given":"Stephen","family":"Apple","sequence":"additional","affiliation":[{"name":"Tanabe Pharma America, Inc.  Jersey City New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1603471"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.235952"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181b6bbbd"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351153"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2021.1936557"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2022.2059380"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117054"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200799"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-016-0050-8"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21661"},{"key":"e_1_2_8_12_1","volume-title":"Prescribing Information","author":"Rilutek (riluzole)","year":"2016"},{"key":"e_1_2_8_13_1","volume-title":"Prescribing Information","author":"Radicava (edaravone) IV and Radicava ORS (edaravone) Oral Suspension","year":"2025"},{"key":"e_1_2_8_14_1","volume-title":"Prescribing Information","author":"QALSODY (tofersen) Injection","year":"2023"},{"key":"e_1_2_8_15_1","volume-title":"Prescribing Information","author":"Relyvrio (Sodium Phenylbutyrate and Taurursodiol)","year":"2022"},{"key":"e_1_2_8_16_1","unstructured":"Amylyx Pharmaceuticals \u201cAmylyx Pharmaceuticals Announces Formal Intention to Remove Relyvrio\/Albrioza from the Market; Provides Updates on Access to Therapy Pipeline Corporate Restructuring and Strategy \u201d2024 https:\/\/www.amylyx.com\/news\/amylyx\u2010pharmaceuticals\u2010announces\u2010formal\u2010intention\u2010to\u2010remove\u2010relyvrior\/albriozatm\u2010from\u2010the\u2010market\u2010provides\u2010updates\u2010on\u2010access\u2010to\u2010therapy\u2010pipeline\u2010corporate\u2010restructuring\u2010and\u2010strategy."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bc01a4"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000180717.29273.12"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.9.1258"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.083402"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2006.03.008"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2015.07.024"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2025.01.012"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2017.1364269"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.952"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.925"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27768"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-021-00250-5"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.011"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2019.1599955"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01271-2"},{"key":"e_1_2_8_33_1","unstructured":"R.vanEijk M.Povedano P.vanDamme et\u00a0al. \u201cTop Line Results of the ADORE Study: An International Phase 3 Trial to Investigate the Efficacy and Safety of Daily Oral Edaravone (FNP122) in ALS \u201dEuropean Network to Cure ALS (ENCALS) 2024 Meeting; 18 June 2024; Stockholm Sweden."},{"key":"e_1_2_8_34_1","unstructured":"L.van denBerg R.vanEijk C.Varona et\u00a0al. \u201cPost\u2010Hoc Analysis of the ADORE Study: An International Phase 3 Trial to Investigate the Efficacy and Safety of Daily Oral Edaravone (FNP122) in ALS. 35th International Symposium on ALS\/MND (2024)\u201d."}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.70036","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:49:05Z","timestamp":1771220945000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.70036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/mus.70036"],"URL":"https:\/\/doi.org\/10.1002\/mus.70036","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}